Noema Pharma
Basel, Switzerland · Biotechnology, Health Care, Therapeutics
Noema Pharma is a clinical-stage biotech company advancing a portfolio of transformative, first-in-disease therapeutics targeting neuroscience-based conditions with high unmet need. Noema has four programs currently in active Phase 2 clinical trials evaluating seizures in Tuberous Sclerosis Complex, pain in Trigeminal Neuralgia, Tourette syndrome and vasomotor symptoms plus CNS-mediated symptoms o
Key facts
- Headquarters
- Basel, Switzerland
- Employees
- 32
- Industries
- Biotechnology, Health Care, Therapeutics
- Status
- Private
- Website
- noemapharma.com
- Company page
Recent activity at Noema Pharma
- : Noema Pharma Appoints Michael Samar as Chief Financial Officer and Volker Knappertz as Executive Vice President of Research and Development
- : Noema Pharma raised $147 Million in a Series B financing round led by EQT Life Sciences to support its Phase 2 trials for CNS disorders.
- : Noema Pharma Appoints Robert Lasser, M.D., as Chief Medical Officer
Noema Pharma funding history
| Date | Round | Amount |
|---|---|---|
| Dec 2024 | Series B | $147.0M |
Leadership
- Volker Knappertz, Vice President of Research and Development
- Michael Samar, Chief Financial Officer
- Ilise Lombardo, Chief Executive Officer
- Robert Lasser, Chief Medical Officer
Verified email and direct lines for Noema Pharma’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Noema Pharma in the news
- Noema Pharma extends Series B financing round, closing at CHF 130 Million ($147 Million) - Business Wire (Dec 11, 2024)
- Rebecca Dunsmoor-Su, MD, highlights reduced hot flashes from cendifensine - Contemporary OB/GYN (Dec 04, 2025)
- Noema Pharma raises CHF54 million in Series A financing round led by Sofinnova Partners and Polaris Partners - GlobeNewswire (Dec 01, 2020)
- Noema Pharma, Founded by Sofinnova Partners, Raises CHF 103 Million (USD 112 Million) in Series B Financing - Business Wire (Mar 07, 2023)
Companies similar to Noema Pharma
- AIM ImmunoTech · Biotechnology, Health Care, Therapeutics
- Gain Therapeutics · Biotechnology, Health Care, Therapeutics
- ProteinQure · Biotechnology, Health Care, Therapeutics
- STORM Therapeutics · Biotechnology, Health Care, Therapeutics
- Qualigen Therapeutics · Biotechnology, Health Care, Therapeutics
About Noema Pharma: questions and answers
What does Noema Pharma do?
Noema Pharma is a clinical-stage biotech company advancing a portfolio of transformative, first-in-disease therapeutics targeting neuroscience-based conditions with high unmet need. Noema has four programs currently in active Phase 2 clinical trials evaluating seizures in Tuberous Sclerosis Complex, pain in Trigeminal Neuralgia, Tourette syndrome and vasomotor symptoms plus CNS-mediated symptoms o
Where is Noema Pharma headquartered?
Noema Pharma is headquartered in Basel, Switzerland.
How many employees does Noema Pharma have?
Noema Pharma has about 32 employees.
Has Noema Pharma raised funding?
Yes. Fundz has recorded 1 funding event for Noema Pharma. The most recent, Series B of $147.0M, was in Dec 2024.
Who leads Noema Pharma?
Volker Knappertz is a Vice President of Research and Development at Noema Pharma.
What is the latest news on Noema Pharma?
On Jan 08, 2025, Noema Pharma Appoints Michael Samar as Chief Financial Officer and Volker Knappertz as Executive Vice President of Research and Development
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy